You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
紅日藥業(300026.SZ)擬6000萬元購買億諾瑞25%股權
格隆匯 01-21 21:55

格隆匯1月21日丨紅日藥業(300026.SZ)公佈,公司此次交易的主要內容為:公司擬以自有資金人民幣6000萬元向湖北五瑞生物科技股份有限公司(“五瑞生物”)購買公司控股子公司湖北億諾瑞生物製藥有限公司(“億諾瑞”、“標的公司”、“目標公司”)25%的股權。此次交易完成後,公司將持有億諾瑞75.92%的股權,此次交易前後公司均為億諾瑞的控股股東。

湖北億諾瑞生物製藥有限公司是一家專注於肝素鈉、低分子肝素系列原料研發生產的生物製藥企業。億諾瑞是國內肝素行業唯一擁有從豬小腸加工、粘膜肝素到原料藥完整產業鏈的企業,也是實現分級低分子肝素原料藥系列品種產業化的企業。主要經營範圍:腸衣、肝素鈉粗品、肝素類原料藥生產、銷售。主要生產品種:肝素鈉、肝素鈣、低分子量肝素鈣、依諾肝素鈉、那屈肝素鈣、達肝素鈉等原料藥品種,以及肝素鈉粗品、腸衣、類肝素等。

億諾瑞以打造國際化肝素產業平台為目標,整合上下游優質資源,形成了從豬小腸加工、粘膜肝素提取、肝素原料藥到分級低分子肝素原料藥的完整肝素產業鏈。依託紅日藥業現有低分子量肝素鈣製劑以及計劃今後實施的預灌裝分級低分子肝素注射液項目,具備從原料到終端的產業鏈優勢。是國內少數幾家具有從上游資源、API原料藥到下游製劑(配套紅日藥業)完整產業鏈的肝素類製藥企業。

此次交易符合國家相關政策且有利於億瑞諾各項業務開展,充分發揮公司整合優勢,提升核心競爭力和高質量發展。同時增強億瑞諾自身資金實力,有利於降低資產負債率水平,優化債務結構,進一步提升綜合競爭能力。此次交聯交易不存在有損公司利益和中小投資者權益的行為。

此次交易完成後,公司將密切關注億諾瑞的經營情況,並強化對子公司的管理控制,主動防範經營與財務風險。此次交易不會對公司本期財務報表與經營狀況產生重大影響。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account